Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression

Author(s): Benjamin Johnson, Takuya Osada, Timothy Clay, Herbert Lyerly, Michael Morse

Journal Name: Current Molecular Medicine

Volume 9 , Issue 6 , 2009

Become EABM
Become Reviewer
Call for Editor


Vascular endothelial growth factor (VEGF), known as a primary mediator of tumor-induced angiogenesis, is now understood to have a role in tumor-associated immunosuppression. Initially, VEGF was identified to alter the growth and maturation of the immature granulocyte-macrophage progenitors, and more recently it has been noted that it prevents dendritic cell (DC) precursors from developing into mature, antigenpresenting DC. VEGF is associated with recruitment of macrophages to the tumor stroma and VEGF inhibition of myeloid progenitor maturation is associated with the development tumor associated macrophages (TAM) which possess immunosuppressive capacity as well. Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [702 - 707]
Pages: 6
DOI: 10.2174/156652409788970634
Price: $65

Article Metrics

PDF: 10